Respira Therapeutics, a privately held pharmaceutical company developing innovative inhaled therapies to treat pulmonary hypertension and other pulmonary diseases, has entered into a strategic collaboration with United Therapeutics Corporation for the development and exclusive license of Respira’s inhaled drug-device product, RT234, for pulmonary hypertension indications in North America.
According to collaboration agreement, United Therapeutics will provide Respira with non-dilutive development funding to advance RT234 through FDA approval, Respira said. Additionally, United Therapeutics will be the lead investor in Respira’s Series B preferred stock financing.
Respira said that its current investors, Cottonwood Technology Fund and Sun Mountain Capital, will also be part of collaboration. Respira will continue to advance the development of its other pipeline programs and will retain full control of its R&D programs outside of pulmonary hypertension, the company said.
Bob Curtis, President and CEO of Respira said: “This important investment and strategic collaboration will allow our company to capitalize on the innovative research pipeline we have developed.“